CL2020002284A1 - Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc) - Google Patents

Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)

Info

Publication number
CL2020002284A1
CL2020002284A1 CL2020002284A CL2020002284A CL2020002284A1 CL 2020002284 A1 CL2020002284 A1 CL 2020002284A1 CL 2020002284 A CL2020002284 A CL 2020002284A CL 2020002284 A CL2020002284 A CL 2020002284A CL 2020002284 A1 CL2020002284 A1 CL 2020002284A1
Authority
CL
Chile
Prior art keywords
crystalline forms
sgc
stimulant
guanylyl cyclase
soluble guanylyl
Prior art date
Application number
CL2020002284A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Storz
Kwame W Nti-Addae
Leena Kumari Prasad
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65818696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020002284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of CL2020002284A1 publication Critical patent/CL2020002284A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2020002284A 2018-03-07 2020-09-03 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc) CL2020002284A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07

Publications (1)

Publication Number Publication Date
CL2020002284A1 true CL2020002284A1 (es) 2020-11-27

Family

ID=65818696

Family Applications (5)

Application Number Title Priority Date Filing Date
CL2020002284A CL2020002284A1 (es) 2018-03-07 2020-09-03 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)
CL2021000301A CL2021000301A1 (es) 2018-03-07 2021-02-04 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020.
CL2021003530A CL2021003530A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.
CL2021003536A CL2021003536A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020
CL2021003531A CL2021003531A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020

Family Applications After (4)

Application Number Title Priority Date Filing Date
CL2021000301A CL2021000301A1 (es) 2018-03-07 2021-02-04 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020.
CL2021003530A CL2021003530A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.
CL2021003536A CL2021003536A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020
CL2021003531A CL2021003531A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020

Country Status (21)

Country Link
US (3) US11466015B2 (OSRAM)
EP (1) EP3762389B1 (OSRAM)
JP (1) JP7423539B2 (OSRAM)
KR (1) KR102782810B1 (OSRAM)
CN (1) CN111836812A (OSRAM)
AU (1) AU2019231724B2 (OSRAM)
BR (1) BR112020018212A2 (OSRAM)
CA (1) CA3092683A1 (OSRAM)
CL (5) CL2020002284A1 (OSRAM)
CO (1) CO2020012493A2 (OSRAM)
CR (1) CR20200458A (OSRAM)
EA (1) EA202092109A1 (OSRAM)
ES (1) ES2980256T3 (OSRAM)
IL (1) IL276853B2 (OSRAM)
MA (1) MA54638A (OSRAM)
MX (5) MX2023004856A (OSRAM)
PE (1) PE20210124A1 (OSRAM)
PH (1) PH12020551394A1 (OSRAM)
SG (1) SG11202008641WA (OSRAM)
TW (1) TWI823903B (OSRAM)
WO (1) WO2019173551A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3092683A1 (en) 2018-03-07 2019-09-12 Cyclerion Therapeutics, Inc. Crystalline forms of an sgc stimulator
JP7542518B2 (ja) * 2018-07-11 2024-08-30 ティセント セラピューティクス インコーポレーテッド ミトコンドリア（ｍｉｔｏｃｈｏｎｒｉａｌ）障害の処置のためのｓＧＣ刺激剤の使用
WO2021195403A1 (en) * 2020-03-26 2021-09-30 Cyclerion Therapeutics, Inc. Deuterated sgc stimulators
WO2024131860A1 (zh) * 2022-12-21 2024-06-27 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
AU2023412228A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100720844B1 (ko) 1998-07-08 2007-05-25 사노피-아벤티스 도이칠란트 게엠베하 황 치환된 설포닐아미노카복실산 ｎ-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CA2698332C (en) 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Pyrazole derivatives as soluble guanylate cyclase activators
US7947664B2 (en) 2008-01-24 2011-05-24 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
US8741910B2 (en) 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
WO2011119518A1 (en) 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MA34330B1 (fr) 2010-05-27 2013-06-01 Merck Sharp & Dohme Activateurs de guanylate cyclase soluble
WO2012003405A1 (en) 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
NZ609955A (en) 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
CN104822680B (zh) 2012-11-30 2016-10-12 安斯泰来制药株式会社 咪唑并吡啶化合物
CN105339368B (zh) 2013-06-04 2017-08-15 拜耳制药股份公司 3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途
CN104327107A (zh) 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
WO2015187470A1 (en) 2014-06-04 2015-12-10 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
CA2961489A1 (en) 2014-09-17 2016-03-24 Glen Robert RENNIE Sgc stimulators
CN107257796A (zh) 2014-12-02 2017-10-17 拜耳医药股份有限公司 取代的吡唑并[1,5‑a]吡啶和咪唑并[1,2‑a]吡嗪及其用途
EP3872080B1 (en) 2016-09-02 2023-08-16 Cyclerion Therapeutics, Inc. Fused bicyclic sgc stimulators
CA3092683A1 (en) 2018-03-07 2019-09-12 Cyclerion Therapeutics, Inc. Crystalline forms of an sgc stimulator

Also Published As

Publication number Publication date
CR20200458A (es) 2020-11-09
BR112020018212A2 (pt) 2020-12-29
CA3092683A1 (en) 2019-09-12
JP2021515015A (ja) 2021-06-17
TWI823903B (zh) 2023-12-01
WO2019173551A1 (en) 2019-09-12
US11466015B2 (en) 2022-10-11
EA202092109A1 (ru) 2021-03-04
JP7423539B2 (ja) 2024-01-29
US20250115611A1 (en) 2025-04-10
MX2023004858A (es) 2023-11-24
MX2023004857A (es) 2023-11-24
TW201940487A (zh) 2019-10-16
KR102782810B1 (ko) 2025-03-14
CL2021000301A1 (es) 2021-06-18
KR20200128708A (ko) 2020-11-16
PH12020551394A1 (en) 2021-11-22
AU2019231724A1 (en) 2020-10-08
CN111836812A (zh) 2020-10-27
CL2021003531A1 (es) 2022-08-19
US12122782B2 (en) 2024-10-22
PE20210124A1 (es) 2021-01-19
CL2021003536A1 (es) 2022-08-19
MA54638A (fr) 2021-11-10
MX2023004855A (es) 2023-11-24
EP3762389A1 (en) 2021-01-13
WO2019173551A8 (en) 2020-06-11
US20210115050A1 (en) 2021-04-22
AU2019231724B2 (en) 2024-06-27
MX2023004856A (es) 2023-11-24
SG11202008641WA (en) 2020-10-29
CO2020012493A2 (es) 2020-10-30
EP3762389B1 (en) 2024-02-28
IL276853B1 (en) 2026-01-01
IL276853A (en) 2020-10-29
US20230095799A1 (en) 2023-03-30
CL2021003530A1 (es) 2022-08-19
MX2020009183A (es) 2020-10-08
ES2980256T3 (es) 2024-09-30
IL276853B2 (en) 2026-05-01

Similar Documents

Publication Publication Date Title
CO2020012493A2 (es) Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)
PE20181802A1 (es) Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d]pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovasculares
PY2224252A (es) 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek
CO2021002651A2 (es) Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
MX388140B (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
ECSP20078226A (es) Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20201185A1 (es) Inhibidores de la oxacina monoacilglicerol lipasa (magl)
MX376465B (es) Compuestos de pirazolo[1,5-4]piridina sustituidos como inhibidores de la quinasa ret.
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
MX370000B (es) Novedosas n-acil-(3-sustituidas)-(8-sustituidas)-5,6-dihidro-[1,2, 4]triazolo[4,3-a]piracinas como antagonistas selectivos del receptor de nk-3, composición farmacéutica y métodos para su uso en trastornos mediados por el receptor de nk-3.
MX2020008237A (es) Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias.
ES2721018T3 (es) N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3
SG10201907576SA (en) Salts of pi3k inhibitor and processes for their preparation
CL2017001380A1 (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
SG10201809189UA (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use
UY30706A1 (es) Diaril, dipiridinil y arilpiridinil derivados y usos de los mismos
MX2022014858A (es) Formas solidas de pralsetinib.
JOP20170125A1 (ar) مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] (1h-1، 2، 3-تريازول-4-يل) ميثانون
UY28524A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
EP4606433A8 (en) FORMULATIONS CONTAINING HETEROCYCLIC PROTEIN KINASE INHIBITORS
PA8592801A1 (es) Derivados biciclicos para el tratamiento del crecimiento celular anormal
CL2013000434A1 (es) Compuestos derivados de 6,7-dihidro-3h-oxazolo(3,4) pirazina-5,8-diona, composicion farmaceutica que los comprende; proceso para prepararlos, y uso en el tratamiento de patologias mediadas por inhibicion de la emzima pde-5, como disfuncion erectil, litiasis, hiperplasia prostatica, disfuncion sexual femenia.
AR037753A1 (es) Nuevas fitasas y procedimiento de produccion de dichas fitasas
MX2022005639A (es) Compuestos inhibidores de pde-5 y/o pde-6 donadores de oxido de nitrogeno.